Navigation Links
Penn researchers identify potential target for breast cancer therapy
Date:12/22/2010

PHILADELPHIA Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients. However, not all patients' tumors respond, with some becoming resistant over time. Different drugs that interfere with other steps in the signaling pathway may improve the response of patients, yet little is known about these molecules.

Now, Marcelo G. Kazanietz, PhD, professor of Pharmacology at the University of Pennsylvania School of Medicine and colleagues, report that a protein called P-Rex1 is crucial for signal transmission from ErbB receptors. What's more, they found that P-Rex1 is overexpressed in nearly 60 percent of breast cancer samples tested and patients whose tumors express P-Rex1 were more likely to develop metastasis, compared with those whose tumors did not express P-Rex1.

"We identified a downstream target of the ErbB receptors which seems to be crucial for cancer cell proliferation, migration, and metastasis," Kazanietz says. "Understanding how this pathway works should allow us to find new drugs or therapeutic approaches in the future."

The team's research is featured on the cover of the December 22 issue of Molecular Cell.

A Well-Known Family

The ErbB family of receptors is well known in the cancer world. The family includes the epidermal growth factor receptor (EGFR, also known as ErbB1); ErbB2 (also known as HER2/neu), which is the target of Herceptin; as well as ErbB and ErbB4.

Previous work from Kazanietz and others suggested the receptors might rely on small proteins in the Rac pathway to help transmit their signal. To find out if that was the case, Kazanietz and colleagues examined human breast cancer cell lines and found that one Rac pathway protein, P-Rex1, is overexpressed in numerous cell lines compared with normal mammary cells. The team also found that P-Rex1 is present in some breast tumors, particularly those that express the Her2/neu receptor or estrogen receptor and belong to the luminal subtype.

"We found that about two-thirds of the patient samples had very high levels of P-Rex1 expression in tumor cells in their lymph nodes," Kazanietz says. "There seems to be a correlation between P-Rex1 expression in the tumor cells and the capacity of these cells to metastasize. And since P-Rex1 is likely to be essential for cell migration and migration is essential for metastasis, we believe blocking this pathway could reduce the risk of metastasis."

P-Rex1 may be important for several other cancer-promoting pathways. For example, estrogen-receptor signaling also appears to rely on P-Rex1, which means that targeted inhibitors of P-Rex1 might improve responses to anti-estrogen therapies such as tamoxifen.

The authors also found that P-Rex1 is also used by another receptor, CXCR4, which has recently shown up in many cancer studies. Despite being used in numerous pathways during cancerous growth, P-Rex1 is not expressed in many normal tissues. "That gives us a very good target. It is really cancer specific," Kazanietz says. "What's more, as P-Rex1 is expressed in some subtypes of breast tumors, it may be an excellent prototype for future personalized medicine."

Preclinical data from other groups supports the importance of the Rac pathway in cancer, according to Kazanietz. And small molecule inhibitors that block proteins in the Rac pathway appear to have strong anti-cancer effects in model systems, though their use in patients still needs to be tested.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related medicine news :

1. Researchers Turn White Fat to Energy-Burning Brown Fat in Mice
2. Finnish researchers find a compound that prevents the growth of prostate cancer cells
3. Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children
4. Breast inflammation is key to cancer growth, Kimmel Cancer Center researchers say
5. Researchers discover new signaling pathway linked to inflammatory disease
6. UCI researchers find novel memory-enhancing mechanism in brain
7. Researchers make critical leukemia stem cell discovery
8. U-M researchers discover way to block neurodegeneration in an adult form of Fragile X syndrome
9. Leibniz Prize 2011: 10 researchers awarded €2.5 million ($3.3 million) each
10. Researchers Turn Stem Cells Into Intestinal Tissue in Lab
11. Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn researchers identify potential target for breast cancer therapy
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, a national ... category winner, has named Daniel P. Bullington as chief technology officer. , “i2i ... and product offerings,” says Justin Neece, president. “Daniel is an excellent fit for ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment ... collagen and elastin in their face, neck, and body through a virtually pain-free, ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech ... in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at ... NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... May 4, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... the "Company"), today announced that the Company,s first quarter ... on Thursday, May 11, 2017, and that the Company ... 1:30 p.m. PT that afternoon. Management will provide an ...
(Date:5/3/2017)... 2017  Getinge, a leading global provider of ... and cost efficiency within healthcare and life sciences, ... practice demonstrating that intra-aortic balloon counterpulsation (IABC) appears ... patients. The single-center, retrospective, observational study showed that ... ® 50cc intra-aortic balloon (IAB) in contemporary ...
(Date:5/2/2017)... May 2, 2017  George Clinical, a leading full-service ... region, and Vector Oncology, a Memphis ... formally announced today that George Clinical has acquired ... has the dual purpose of strengthening the ability ... trial delivery solutions throughout the Asia-Pacific ...
Breaking Medicine Technology: